Table 4.
Baseline and end point means and standard deviations for primary and secondary outcome measures by treatment group.
| Placebo (N=30) | Nefazodone (N=36) | Bupropion (N=40) | Statistic* | p-value | ||||
|---|---|---|---|---|---|---|---|---|
| Outcome | Baseline | Week 10 | Baseline | Week 10 | Baseline | Week 10 | ||
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |||
| Abstinent (%) | - | 7 (70%) | - | 8 (50%) | - | 4 (31%) | X2=3.50 | 0.17 |
| Dependence Severity(CGI) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||
| Severity Rating | 4.6 (0.8) | 2.3 (1.6) | 4.6 (0.9) | 2.5 (1.4) | 4.8 (1.0) | 2.7 (1.5) | F2,39=0.26 | 0.77 |
| Improvement Rating | - | 1.4 (0.7) | - | 1.9 (1.0) | - | 1.7 (0.9) | F2,39=1.42 | 0.25 |
| Withdrawal Symptoms | ||||||||
| Snaith Irritability Scale | ||||||||
| Inward Irritability | 3.4 (3.0) | 2.5 (3.4) | 3.4 (2.7) | 1.9 (1.5) | 4.3 (2.8) | 2.6 (3.1) | F2,35=0.28 | 0.75 |
| Outward Irritability | 4.0 (2.5) | 1.9 (1.9) | 4.5 (2.5) | 3.1 (1.9) | 4.6 (2.8) | 4.0 (2.1) | F2,35=3.25 | 0.05 |
| SMHSQ | ||||||||
| Difficulty Falling Asleep | 1.3 (0.6) | 1.1 (0.3) | 1.6 (0.9) | 1.0 (0) | 1.6 (0.7) | 1.5 (0.9) | F2,37=2.97 | 0.06 |
| Sleep Disturbances (# of times awakened) | 1.4 (1.2) | 1.3 (1.2) | 1.6 (1.6) | 1.1 (1.3) | 1.4 (1.7) | 1.0 (1.2) | F2,37=0.16 | 0.86 |
| HAM-A | 7.5 (6.6) | 4.8 (4.3) | 5.6 (4.8) | 2.4 (3.3) | 6.0 (4.9) | 3.9 (5.3) | F2,22=0.63 | 0.54 |
*
Chi-square statistic was performed for the binary primary outcome. Analysis of variance was performed to compare the mean Week 10 values for the continuous secondary outcomes